Premium
5‐Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer
Author(s) -
Muss Hyman B.,
Lokich Jacob J.,
Frei Emil
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975182234
Subject(s) - leukopenia , medicine , fluorouracil , dose , drug , gastrointestinal cancer , chemotherapy , regimen , pharmacology , cytosine , gastroenterology , bone marrow suppression , cytarabine , antimetabolite , cancer , colorectal cancer , chemistry , dna , biochemistry
A 2‐drug combination chemotherapy regimen of 5‐fluorouracil (FU) and cytosine arabinoside (ara‐C) was used in 23 patients with gastrointestina1 cancer. The drugs were administered as a mixture by daily continuous infusion for 5 days at 4‐wk intervals. Dosages for each drug were: FU, 1.1 gm/m 2 /day and ara‐C, 50 mg/m 2 /day, The incidence of leukopenia (WBC, <3,500/mm 3 ) was 36% and of thrombocytopenia (platelets, <125,000/mm 3 ), 18% during 33 courses administered at full doses. No clinical antitumor effects were observed in 18 patients evaluable for therapeutic response. The addition of ara‐C to a nonmyelosuppressive dose schedule of FU results in potentiated marrow suppression, and the antitumor effect for the combination is less than would have been predicted for either drug alone.